Pelvic exenteration surgery in patients with locally advanced castration-naïve and castration-resistant, symptomatic prostate cancer.
Axel HeidenreichMark BludauChristiane BrunsTim NestlerDaniel PorresDavid Johannes Karl Paul PfisterPublished in: BJU international (2020)
Pelvic exenteration surgery is technically feasible in well-selected patients, resulting in symptom relief in >90% of patients, covering 80% of their remaining lifetime.
Keyphrases
- prostate cancer
- end stage renal disease
- minimally invasive
- newly diagnosed
- ejection fraction
- chronic kidney disease
- rectal cancer
- locally advanced
- prognostic factors
- squamous cell carcinoma
- coronary artery bypass
- clinical trial
- radical prostatectomy
- coronary artery disease
- atrial fibrillation
- neoadjuvant chemotherapy
- percutaneous coronary intervention